One of the cleaner ones, a 24-week randomized study of 279 mild-to-moderate Alzheimers patients, tested three doses against placebo and found a result no marketer would have designed: the lowest dose, 10 mL a day, beat placebo on both a cognitive scale and a global clinical rating, while the higher 30 and 60 mL doses improved the global rating but not cognition (Alvarez et al., Eur J Neurol 2006, randomized controlled trial)
The development of enzyme-inhibiting peptides requires careful consideration of selectivity and duration of action
Sun Y, Wei R, Yan D, Xu F, Zhang X, Zhang B, et al
Frequently Asked Questions What makes GHK-Cu one of the best peptides for anti-aging research
Think of it this way: you wouldn't store a high-purity peptide from Home on a sunny windowsill